• Insmed Inc., of Monmouth Junction, N.J., began screening patients for TARGET-NTM (Treatment with ARIKACE to Realize Greater Efficacy Trial), its U.S. Phase II trial of Arikace (liposomal amikacin for inhalation) in nontuberculous mycobacterial lung disease.